Information Provided By: 
Fly News Breaks for November 5, 2019
VIR
Nov 5, 2019 | 07:13 EDT
JPMorgan analyst Anupam Rama initiated coverage of Vir Biotechnology with an Overweight rating and $25 price target. The company's four distinct technology platforms offer long-term pipeline optionality across multiple infectious disease indications, Rama tells investors in a research note. He believes the scientific rationale across the platforms allows Vir to approach infectious diseases from multiple angles, "some of which are potentially synergistic."
News For VIR From the Last 2 Days
There are no results for your query VIR
